Newsletter Archive
-
04.16.24 -- Streamline Oligo Production With A Comprehensive Equipment Range
4/16/2024
04/16/24 Bioprocess Online Newsletter
-
04.16.24 -- Continuous Manufacturing: Many Want It, But Here's Why Few Have It
4/16/2024
04/16/24 Bioprocess Online Newsletter
-
04.15.24 -- Novel Approaches In Chromatography Process Development
4/15/2024
04/15/24 Bioprocess Online Newsletter
-
04.15.24 -- Stable Cell Lines: Stepping Stones For Continuous Viral Vector Manufacturing
4/15/2024
04/15/24 Bioprocess Online Newsletter
-
04.12.24 -- Is FDA's COVID Container Closure System Guidance Useful Post-Pandemic?
4/12/2024
04/12/24 Bioprocess Online Newsletter
-
04.11.24 -- New DSCSA Guidance Details Layers Of Verification System Requirements
4/11/2024
04/11/24 Bioprocess Online Newsletter
-
04.10.24 -- Considerations For Robust Implementation Of The Multi-Attribute Method
4/10/2024
04/10/24 Bioprocess Online Newsletter
-
04.09.24 -- Comparability Considerations For mRNA Product Development
4/9/2024
04/09/24 Bioprocess Online Newsletter
-
04.08.24 -- What Proposed Plasmid DNA Standards Say For GMP/Non-GMP Production
4/8/2024
04/08/24
-
04.05.24 -- New Episodes: Allogeneic Cell Therapy Toxicities (and how to reduce them); Biotech and The Innovator's Dilemma.
4/5/2024
04/05/24 Bioprocess Online Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more